Treatment of Dilated Blood Vessels on the Cheeks With a New Yellow Laser and a Traditional Green Laser

Rosacea Clinical Trial

Official title:

Treatment of Dilated Blood Vessels on the Cheeks With a New Yellow Laser and a Traditional Green Laser

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03472859
• Other study ID #: R17111
• Status: Completed
• Phase: N/A
• Start date: October 1, 2017
• Est. completion date: June 9, 2018

Study information

• Verified date: February 2018
• Source: Tampere University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal is to compare a novel yellow laser, based on semiconductor technology, with traditional green laser, in the treatment of cheek telangiectasias. The trial design is randomized split-face double-blinded study with 20-30 volunteers. The improvement will be assessed using a 7-point Telangiectasia Grading Scale.

Description:

Trial design: The study is a comparative randomized split-face double-blinded study without a control group. It enables a comparison between two lasers; namely the KTP laser and the investigational PHOTOLASE laser. The split-face design eliminates the individual biases and the randomization eliminates the possible small variations in the symmetry of the telangiectasias on the face. The double-blinded assessment eliminates the physicians' and the subjects' subjective and objective bias.

Methods: The subjects will be treated with a 532-nm green KTP laser and a 585-nm yellow PHOTOLASE laser; different laser on each side of a face. A total of one or two treatments will be given based on the response of the first treatment. The improvement of subjects' telangiectasia will be graded after the final treatment according to a 7-point Telangiectasia Grading Scale (TGS) by a blinded physician using images taken with Visia imaging system. The usability, reliability and treatment characteristics of PHOTOLASE laser will be qualitatively assessed by the treating physicians (not blinded).

Objectives: The primary objective is to assess how the PHOTOLASE laser compares to the KTP laser in the treatment of facial telangiectasia in terms of the treatment outcomes. The secondary objective is to assess the usability, reliability and treatment characteristics of the PHOTOLASE laser from the perspective of the user.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: June 9, 2018
• Est. primary completion date: June 9, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The subjects are required to be Finnish speaking adults with symmetrical facial telangiectasia, volunteering to participate in the clinical trial.

• The subjects have to have a Fitzpatrick skin phototype I-IV.

Exclusion Criteria:

• pregnancy

• lactation

• hemophilic condition

• Fitzpatrick skin phototype V-VI

• drug or alcohol abuse

• subjects who are under guardianship

• subjects with significant tanning less than 6 weeks prior to the treatment day.

• unbalanced basic diseases, such as diabetes, heart disease, cancer etc.

Related Conditions & MeSH terms

• Rosacea
• Telangiectasia
• Telangiectasis

Intervention

Device:
• PHOTOLASE
This is the investigational yellow laser (PHOTOLASE)
• KTP
This is the traditional green laser (KTP)

Locations

Country	Name	City	State
Finland	Epilaser Oy	Lempäälä	Pirkanmaa

Sponsors (2)

Lead Sponsor	Collaborator
Tampere University Hospital	Tampere University of Technology

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	TGS change	Telangiectasia grading scale will be used to assess improvement of telangiectasia and erythema. The range of TGS is -1 to 5, where -1 means worsening of the condition, 0 means no change, 1 means 0-25% improvement, 2 means 25-50% improvement, 3 means 50-75% improvement, 4 means 75-100% improvement and 5 means total clearance.	Before treatment and 1-2 months after the intervention.
Secondary	VAS pain measurement	Visual Analogue Scale will be used to measure the amount of pain after the intervention. The range is 0.0 - 10.0, where 0 means no pain and 10 means worst imaginable pain. The results will be reported as a mean value and range for yellow laser and green laser separately.	Immediately after intervention.
Secondary	Amount of treatment-related adverse effects using a 4-point scale.	The amount of erythema, crusting, edema, purpura and blisters will be assessed separately on both sides of the face. The measurement range is 0-3, where 0 means no symptoms, 1 means mild symptoms, 2 means moderate symptoms and 3 means severe symptoms. The results will be reported as a mean value for yellow laser and green laser separately.	Immediately after treatment and 2-3 days after treatment.